[开放获取]   佩索利单抗治疗炎症性皮肤病专家共识（2026版）

doi:10.35541/cjd.20250147

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (2): 113-119.doi: 10.35541/cjd.20250147

[开放获取] 佩索利单抗治疗炎症性皮肤病专家共识（2026版）

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会

收稿日期:2025-03-24 修回日期:2025-10-14 发布日期:2026-02-03
通讯作者: 晋红中；顾恒 E-mail:jinhongzhong@263.net; guheng@aliyun.com
基金资助:
北京市自然科学基金（7242109）；国家重点研发计划（2022YFC3601800）；中央高水平医院临床科研专项（2022-PUMCH-B-092）；国家临床重点专科建设项目；北京市临床重点专科建设项目

Expert consensus on spesolimab in the treatment of inflammatory skin diseases （2026 edition）

Chinese Society of Dermatology; China Dermatologist Association; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; Rare Skin Diseases Committee, China Alliance for Rare Diseases

Chinese Society of Dermatology; China Dermatologist Association; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; Rare Skin Diseases Committee, China Alliance for Rare Diseases

Received:2025-03-24 Revised:2025-10-14 Published:2026-02-03
Contact: Jin Hongzhong; Gu Heng E-mail:jinhongzhong@263.net; guheng@aliyun.com
Supported by:
Beijing Natural Science Foundation （7242109）; National Key Research and Development Program of China （2022YFC3601800）; National High Level Hospital Clinical Research Funding （2022-PUMCH-B-092）; National Key Clinical Specialty Project of China; Key Clinical Specialty Project of Beijing

摘要/Abstract

摘要： 【摘要】白细胞介素36通路在泛发性脓疱型银屑病（GPP）等多种炎症性皮肤病的发病机制中起关键作用，以佩索利单抗为代表的抗白细胞介素36R单克隆抗体为GPP等多种炎症性皮肤病的治疗提供了更多选择。中华医学会皮肤性病学分会、中国医师协会皮肤科医师分会等召集相关领域专家制订本共识，对佩索利单抗治疗GPP、局限性脓疱型银屑病、化脓性汗腺炎、坏疽性脓皮病、急性发热性嗜中性皮病、急性泛发性发疹性脓疱病等炎症性皮肤病的适用人群、应用方案和安全性管理等给出建议，为佩索利单抗的临床应用提供参考。佩索利单抗在儿童、妊娠期女性、老年人等特殊人群中的应用尚需更多临床证据的支持，未来需要积累佩索利单抗在GPP中的长期疗效与安全性数据，并拓展其在炎症性皮肤病尤其是难治性嗜中性粒细胞皮肤病中的应用前景。

关键词: 抗IL-36R单克隆抗体, 佩索利单抗, 炎症性皮肤病, 泛发性脓疱型银屑病, 专家共识

Abstract: 【Abstract】 The interleukin-36 pathway plays an important role in the pathogenesis of various inflammatory skin diseases, including generalized pustular psoriasis （GPP）. Anti-interleukin-36R monoclonal antibodies, represented by spesolimab, provide more therapeutic options for GPP and other inflammatory skin diseases. The Chinese Society of Dermatology, the China Dermatologist Association, and other institutions convened experts in the relevant field to develop this consensus to provide recommendations on the indications, treatment regimens, and safety management of spesolimab in inflammatory skin diseases, such as GPP, localized pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, acute febrile neutrophilic dermatosis, and acute generalized exanthematous pustulosis, with the aim of guiding its clinical application. The application of spesolimab in special populations such as pediatric, pregnant, and elderly patients requires further clinical evidence. Future studies should focus on the long-term efficacy and safety of spesolimab in the treatment of GPP, and explore its potential in treating inflammatory skin diseases, particularly refractory neutrophilic dermatoses.

Key words: anti-IL-36R monoclonal antibodies, spesolimab, inflammatory skin diseases, generalized pustular psoriasis, expert consensus

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 佩索利单抗治疗炎症性皮肤病专家共识（2026版）[J]. 中华皮肤科杂志, 2026,59(2):113-119. doi:10.35541/cjd.20250147

Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Expert consensus on spesolimab in the treatment of inflammatory skin diseases （2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(2): 113-119.doi:10.35541/cjd.20250147

参考文献 49

［1］	Ahmad F, Alam MA, Ansari AW, et al. Emerging role of the IL⁃36/IL⁃36R axis in multiple inflammatory skin diseases［J］. J Invest Dermatol, 2024,144（2）:206⁃224. DOI: 10.1016/j.jid. 2023.11.004.
［2］	Sugiura K, Fujita H, Komine M, et al. The role of interleukin⁃36 in health and disease states［J］. J Eur Acad Dermatol Venereol, 2024,38（10）:1910⁃1925. DOI: 10.1111/jdv.19935.
［3］	Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti⁃interleukin⁃36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phaseⅡGALLOP trial［J］. Br J Dermatol, 2023,189（2）:161⁃169. DOI: 10.1093/bjd/ljad083.
［4］	Qian Q, Yang B, Lu X, et al. Recibokibart, an anti⁃IL⁃36 receptor monoclonal antibody, for treating generalized pustular psoriasis: phase 1b trial［J］. J Eur Acad Dermatol Venereol, 2025,39（6）:e544⁃e546. DOI: 10.1111/jdv.20511.
［5］	Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti⁃interleukin⁃36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase Ⅱa, multicenter, double⁃blind, randomized, placebo⁃controlled pilot study［J］. Dermatol Ther （Heidelb）, 2021,11（2）:571⁃585. DOI: 10.1007/s13555⁃021⁃00504⁃0.
［6］	Burden AD, Bissonnette R, Navarini AA, et al. Spesolimab efficacy and safety in patients with moderate⁃to⁃severe palmoplantar pustulosis: a multicentre, double⁃blind, randomised, placebo⁃controlled, phase Ⅱb, dose⁃finding study［J］. Dermatol Ther （Heidelb）, 2023,13（10）:2279⁃2297. DOI: 10.1007/s13555⁃023⁃01002⁃1.
［7］	Wang Y, Zhang L, Zheng J, et al. Spesolimab response in a girl with acrodermatitis continua of Hallopeau［J］. JAMA Dermatol, 2024,160（4）:476⁃477. DOI: 10.1001/jamadermatol.2023.6349.
［8］	Alavi A, Prens EP, Kimball AB, et al. Proof⁃of⁃concept study exploring the effect of spesolimab in patients with moderate⁃to⁃severe hidradenitis suppurativa: a randomized double⁃blind placebo⁃controlled clinical trial［J］. Br J Dermatol, 2024,191（4）:508⁃518. DOI: 10.1093/bjd/ljae144.
［9］	Zhang H, Wu C, Jin H. Successful treatment of etanercept⁃ and adalimumab⁃resistant pyoderma gangrenosum with spesolimab, moderate⁃dose corticosteroids, and minocycline［J］. J Dermatolog Treat, 2025,36（1）:2451811. DOI: 10.1080/09546634.2025.245 1811.
［10］	Pang Z, Wu C, Liu J, et al. Spesolimab response in a patient with steroid⁃resistant Sweet syndrome［J］. JAMA Dermatol, 2025,161（1）:110⁃112. DOI: 10.1001/jamadermatol.2024.4342.
［11］	Russo G, Dumont S, Menzinger S, et al. Severe acute generalized exanthematous pustulosis successfully treated by spesolimab［J］. Acta Derm Venereol, 2024,104:adv41311. DOI: 10.2340/actadv.v104.41311.
［12］	Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy （SORT）: a patient⁃centered approach to grading evidence in the medical literature［J］. Am Fam Physician, 2004,69（3）:548⁃556.
［13］	Zhu T, Jin H, Shu D, et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis［J］. Eur J Dermatol, 2018,28（2）:217⁃224. DOI: 10. 1684/ejd.2018.3245.
［14］	Choon SE, Foley PA, Asawanonda P, et al. Asia⁃Pacific consensus recommendations on the management of generalized pustular psoriasis［J］. J Dermatol, 2024,51（12）:1579⁃1595. DOI: 10.1111/1346⁃8138.17471.
［15］	《脓疱型银屑病诊疗中国专家共识（2022版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）［J］. 中华皮肤科杂志, 2022,55（3）:187⁃195. DOI: 10.35541/cjd.20210698.
［16］	中国医师协会皮肤科医师分会儿童学组, 中华医学会皮肤性病学分会银屑病学组. 儿童脓疱型银屑病诊疗中国专家共识（2025版）［J］. 中华皮肤科杂志, 2025,58（4）:297⁃306. DOI: 10. 35541/cjd.20240714.
［17］	Bachelez H, Choon S, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. DOI: 10.1056/NEJMoa2111563.
［18］	Tsai T, Zheng M, Ding Y, et al. Efficacy and safety of spesolimab in patients with generalized pustular psoriasis: a subgroup analysis of Chinese patients in the Effisayil 1 trial［J］. Dermatol Ther （Heidelb）, 2023,13（12）:3097⁃3110. DOI: 10.1007/s13555⁃023⁃01037⁃4.
［19］	Ran D, Yang B, Sun L, et al. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis［J］. Clin Exp Dermatol, 2023,48（7）:803⁃805. DOI: 10. 1093/ced/llad108.
［20］	Chen Y, Wang Z, Liang Y, et al. Successful treatment of pediatric generalized pustular psoriasis （GPP） with spesolimab: 5 case reports and evaluations of circulating IL⁃36 levels［J］. J Inflamm Res, 2024,17:8199⁃8206. DOI: 10.2147/JIR.S485077.
［21］	Seishima M, Fujii K, Mizutani Y. Generalized pustular psoriasis in pregnancy: current and future treatments［J］. Am J Clin Dermatol, 2022,23（5）:661⁃671. DOI: 10.1007/s40257⁃022⁃00698⁃9.
［22］	Yang C, Wang Y, Li R, et al. Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab［J］. J Dermatolog Treat, 2024,35（1）:2334791. DOI: 10.1080/0954 6634.2024.2334791.
［23］	Wang N, Yang Q, Wu W, et al. Long⁃term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab［J］. J Dtsch Dermatol Ges, 2024,22（12）:1679⁃1681. DOI: 10.1111/ddg.15571.
［24］	Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares （Effisayil 2）: an international, multicentre, randomised, placebo⁃controlled trial［J］. Lancet, 2023,402（10412）:1541⁃1551. DOI: 10.1016/S0140⁃6736（23）01378⁃8.
［25］	Zhang H, Zhou J, Tang K, et al. Expanding the therapeutic horizons of spesolimab: a review of off⁃label applications for inflammatory skin diseases［J］. J Dermatolog Treat, 2025,36（1）:2460582. DOI: 10.1080/09546634.2025.2460582.
［26］	Xu J, Wang H, Jin H. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations［J］. Expert Rev Clin Immunol, 2023,19（5）:499⁃516. DOI: 10.1080/1744666X.2023.2185775.
［27］	Chularojanamontri L, Silpa⁃Archa N, Pattamadilok B, et al. A retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau［J］. Exp Dermatol, 2024,33（3）:e15055. DOI: 10. 1111/exd.15055.
［28］	Alshareef KM, Abualola AH, Shaheen EA, et al. The efficacy and safety of non⁃biologic and biologic treatments in palmoplantar pustular psoriasis and palmoplantar pustulosis: a systematic review and network meta⁃analysis［J］. Australas J Dermatol, 2025,66（2）:53⁃60. DOI: 10.1111/ajd.14410.
［29］	Huang D, Jiang X, Yang N, et al. Upadacitinib versus acitretin for the resolution of pustules in palmoplantar pustulosis during acute phase: a single⁃center, open⁃label prospective cohort study［J］. Am J Clin Dermatol, 2025,26（5）:843⁃850. DOI: 10.1007/s40257⁃025⁃00971⁃7.
［30］	Zheng J, Ding Y, Shi Y, et al. Case report: successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations［J］. Front Immunol, 2024,15:1440102. DOI: 10.3389/fimmu.2024.1440102.
［31］	Yuan L, Yu X, Shi Y, et al. Acrodermatitis continua of hallopeau: aggravating factors and treatment outcomes of 96 patients［J］. J Dermatolog Treat, 2024,35（1）:2434098. DOI: 10. 1080/09546634.2024.2434098.
［32］	Fang H, Gao XH, Geng SM, et al. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）［J］. Int J Dermatol Venereol, 2021,4（2）:100⁃108. DOI: 10.1097/jd9.0000000000 000157.
［33］	Yamamoto T, Yamasaki K, Yamanaka K, et al. Clinical guidance of pyoderma gangrenosum 2022［J］. J Dermatol, 2023,50（9）:e253⁃e275. DOI: 10.1111/1346⁃8138.16845.
［34］	Guénin SH, Khattri S, Lebwohl MG. Spesolimab use in treatment of pyoderma gangrenosum［J］. JAAD Case Rep, 2023,34:18⁃22. DOI: 10.1016/j.jdcr.2023.01.022.
［35］	Joshi TP, Friske SK, Hsiou DA, et al. New practical aspects of Sweet syndrome［J］. Am J Clin Dermatol, 2022,23（3）:301⁃318. DOI: 10.1007/s40257⁃022⁃00673⁃4.
［36］	Benezeder T, Bordag N, Woltsche J, et al. IL⁃36⁃driven pustulosis: transcriptomic signatures match between generalized pustular psoriasis （GPP） and acute generalized exanthematous pustulosis （AGEP）［J］. J Allergy Clin Immunol, 2025,155（6）:1913⁃1927. DOI: 10.1016/j.jaci.2025.01.046.
［37］	Stadler P, Oschmann A, Kerl⁃French K, et al. Acute generalized exanthematous pustulosis: clinical characteristics, pathogenesis, and management［J］. Dermatology, 2023,239（3）:328⁃333. DOI: 10.1159/000529218.
［38］	Xuan Y, Jin S, Zhang C, et al. Rapid improvement in refractory acute generalized exanthematous pustulosis with spesolimab［J］. JAMA Dermatol, 2024,160（9）:1009⁃1012. DOI: 10.1001/jamadermatol.2024.2311.
［39］	Guy DR, DeVore S, Kirtani V, et al. Generalized pustular psoriasis successfully treated with spesolimab in the setting of metastatic colon cancer［J］. JAAD Case Rep, 2024,50:6⁃8. DOI: 10.1016/j.jdcr.2024.05.016.
［40］	国家传染病医学中心, 复旦大学附属华山医院. 免疫抑制剂与结核潜伏感染激活的临床专家共识（2025版）［J］. 中华传染病杂志, 2024,42（12）:715⁃735. DOI: 10.3760/cma.j.cn311365⁃20250228⁃00064.
［41］	Hackley M, Thampy D, Waseh S, et al. Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation［J］. J Am Acad Dermatol, 2024,90（2）:408⁃410. DOI: 10.1016/j.jaad.2023.09.078.
［42］	中国防痨协会. 非活动性肺结核诊断及预防发病专家共识［J］. 结核与肺部疾病杂志, 2021,2（3）:197⁃201. DOI: 10.3969/j.issn. 2096⁃8493.20210085.
［43］	中华医学会呼吸病学分会, 国家呼吸医学中心. 综合医疗机构结核病发病高危人群的预防性治疗专家共识［J］. 中华结核和呼吸杂志, 2024,47（10）:933⁃945. DOI: 10.3760/cma.j.cn112147⁃20240328⁃00173.
［44］	Pathak GN, Wang E, Dhillon J, et al. Spesolimab: a review of the first IL⁃36 blocker approved for generalized pustular psoriasis［J］. Ann Pharmacother, 2025,59（2）:174⁃183. DOI: 10.1177/10600280241252688.
［45］	林志淼, 晋红中. 依奇珠单抗治疗中重度斑块型银屑病专家共识［J］. 中华临床免疫和变态反应杂志, 2022,16（3）:225⁃231. DOI: 10.3969/j.issn.1673⁃8705.2022.03.001.
［46］	《司库奇尤单抗治疗银屑病专家共识》编写组. 司库奇尤单抗治疗银屑病专家共识［J］. 中华皮肤科杂志, 2024,57（12）:1079⁃1090. DOI: 10.35541/cjd.20240226.
［47］	Bai J, Chen X, Qiao J, et al. Treatment of Netherton syndrome with spesolimab［J］. J Eur Acad Dermatol Venereol, 2025,39（3）:e261⁃e262. DOI: 10.1111/jdv.20244.
［48］	Yang J, Li G, Tan Y, et al. Clinical responses and transcriptomic analysis of spesolimab in a girl with severe dermatitis, multiple allergies and metabolic wasting syndrome［J］. Exp Dermatol, 2025,34（4）:e70097. DOI: 10.1111/exd.70097.
［49］	Iida S, Muramatsu K, Mizuno A, et al. Improvement of acute phase symptoms of pemphigus foliaceus with spesolimab［J］. JAAD Case Rep, 2025,55:40⁃44. DOI: 10.1016/j.jdcr.2024. 08.035.

[1]	《疥疮诊疗中国专家共识（版）》编写委员会专家组. 疥疮诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(1): 1-8.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病专业委员会中国非公立医疗机构协会皮肤专业委员会. [开放获取] 玫瑰痤疮患者教育指导专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 0(1): 20240725-e20240725.
[3]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 局限性硬皮病诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 699-708.
[4]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[5]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 遗传性血管性水肿诊疗路径皮肤科专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 497-502.
[6]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.
[7]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会中国抗癌协会皮肤肿瘤整合康复专业委员会. [开放获取] 色素痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 387-395.
[8]	中华医学会皮肤性病学分会儿童学组中华医学会儿科学分会皮肤性病学组中国康复医学会皮肤病康复专业委员会中国医师协会皮肤科医师分会儿童皮肤病学组. [开放获取] 中国儿童特应性皮炎专病门诊建设及标准化病案管理专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 0(4): 20240338-e20240338.
[9]	何春霞晋红中. 【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314.
[10]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会国家皮肤与免疫疾病临床医学研究中心. 【开放获取】副肿瘤性天疱疮诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 289-296.
[11]	中国医学装备协会皮肤病与皮肤美容分会中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识[J]. 中华皮肤科杂志, 2025, 0(4): 20250344-e20250344.
[12]	中国康复医学会皮肤病康复专业委员会中华医学会皮肤性病学分会中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. [开放获取] 红蓝黄光治疗皮肤病临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(3): 209-215.
[13]	中国医学装备协会皮肤病与皮肤美容分会. 皮肤病靶向治疗专家共识（2025版） [J]. 中华皮肤科杂志, 2025, 58(2): 99-125.
[14]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 坏疽性脓皮病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(12): 1121-1129.
[15]	邵帅王刚. 泛发性脓疱型银屑病的诊疗：进展、挑战及展望[J]. 中华皮肤科杂志, 2025, 58(11): 1015-1019.

[开放获取] 佩索利单抗治疗炎症性皮肤病专家共识（2026版）

Expert consensus on spesolimab in the treatment of inflammatory skin diseases （2026 edition）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

Metrics

本文评价

推荐阅读 10